Mode
Text Size
Log in / Sign up
N/A N=408 Randomized Double-blind Diagnostic

Integrating Pharmacogenetics In Clinical Care

Cardiovascular Disease

Enrolled (actual)
408
Serious AEs
0.0%
Results posted
Feb 2022
Primary outcome: Primary: 12-Month Change in LDL Cholesterol — -1.1; -2.2 mg/dL

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
SLCO1B1 Genotype (Genetic)
Age
Adult, Older Adult · 40+ yrs
Sex
All
Sponsor
VA Office of Research and Development
Primary completion
Dec 2020

Outcome Measures

OutcomeResultp-value
PRIMARY
12-Month Change in LDL Cholesterol
-1.1; -2.2
SECONDARY
Number of Participants With an American College of Cardiology/American Heart Association (ACC/AHA) Guideline Concordant Statin Prescription at 12 Months
12; 14
SECONDARY
Number of Participants With Chart Review Documented Statin-related Myotoxicity at 12 Months
2; 3
SECONDARY
Number of Participants Meeting Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Safe Simvastatin Prescription at 12 Months
193; 215

Summary

This study will determine whether using a genetic test (for the SLCO1B1 gene) can help patients and providers choose the right type and dose of cholesterol-lowering statin medications to lower the risk of cardiovascular disease, while minimizing the muscle pain side effects that sometimes occur with statins.

Eligibility Criteria

Inclusion Criteria

Providers:

  • All providers in Primary Care and Women's Health at VA Boston Healthcare System will be eligible to participate.

Patients:

  • Aged 40-75 years
  • Have no history of statin use
  • Have received VA care for at least the prior 6 months
  • Are a patient of an enrolled provider
  • Meet at least 1 of the following criteria:
  • cardiovascular disease (CVD)
  • diabetes
  • LDL cholesterol value >= 190 mg/dL
  • 10-year CVD risk of 7.5%, calculated with the ACC/AHA 2013 pooled risk equations

Exclusion Criteria

  • Patients will be ineligible if they:
  • Do not meet the inclusion criteria
  • Pregnant
  • Incarcerated or institutionalized
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02871934). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search